EMA reviews injectable iron medicines

The European Medicines Agency’s (EMA) safety committee, PRAC (Pharmacovigilance Risk Assessment Committee), has initiated a review of injectable iron medicines. The review will assess the risk of low blood phosphate levels and related bone problems associated with these treatments. This is a crucial step in ensuring the continued safety of medicines available to EU citizens. The outcome will inform healthcare professionals and patients about potential side effects and necessary precautions.

Read source